Medicaid-insured children have significantly higher diagnosed mental health condition prevalence than commercially insured children, reflecting disparities in access to care and diagnostic practices across insurance types. A comprehensive study examined geographically granular prevalence using 2018 administrative claims data from the entire Medicaid population and a large commercial insurer.
The study population included 32,545,361 Medicaid-insured and 6,383,486 commercially-insured children aged 3-17. Overall diagnosed mental health prevalence was 11.8 percent in the Medicaid population compared to 5.5 percent in the commercially insured population. For Medicaid-insured children, diagnosed condition-specific prevalence was attention deficit hyperactivity disorder (ADHD) at 5.5 percent, depression at 2.7 percent, and anxiety at 0.9 percent. For commercially-insured children, rates were ADHD at 2.3 percent, depression at 0.2 percent, and anxiety at 1.1 percent.
Suburban communities consistently demonstrated higher diagnosed mental health rates than rural areas for both insurance types. Among Medicaid-insured children, suburban-rural prevalence differences were 1.9 percent for overall mental health, 1.4 percent for ADHD, 0.8 percent for depression, and 0.5 percent for anxiety. Similar patterns emerged for commercially-insured children with smaller magnitude differences.
Significant state-level variations were identified. Seven states had significantly lower diagnosed mental health prevalence than 30 or more other states. In 49 of 50 states, Medicaid-insured children had higher diagnosed prevalence than commercially-insured children, with differences varying from 1.4 percent to 20.5 percent. These disparities likely reflect differences between insurance types in provider networks, reimbursement policies, and access barriers rather than actual differences in mental health condition prevalence among children.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-25422-0